Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04584255 (https://clinicaltrials.gov/show/NCT04584255)
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
About the Study
NOTE: This study is no longer enrolling patients.
This study will look at how well the drugs Niraparib (a type of targeted therapy known as a PARP inhibitor) and Dostarlimab (a type of immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To:
NOTE: This study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.